Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HOB Biotech GroupSHSE:688656 +6.68%84 Debt-to-EBITDA is 0.47 as of Jun. 2026, which is 22% below its 10-year median of 0.60. GuruFocus rates SHSE:688656 with a GF Score™ of 84/100 and a GF Value™ of ¥94.07 (Fairly Valued). The stock has 5 warning signs investors should review. Among 475 Medical Devices & Instruments companies, HOB Biotech Group ranks better than 57.89% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for HOB Biotech Group's Debt-to-EBITDA or its related term are showing as below:
SHSE:688656'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.25 Med: 0.6 Max: 3.32
Current: 1.04
During the past 10 years, the highest Debt-to-EBITDA Ratio of HOB Biotech Group was 3.32. The lowest was 0.25. And the median was 0.60.
SHSE:688656's Debt-to-EBITDA is ranked better than 57.89% of 475
companies
in the Medical Devices & Instruments industry
Industry Median: 1.6
vs SHSE:688656: 1.04
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
HOB Biotech Group Debt-to-EBITDA Related Terms
HOB Biotech Group Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for HOB Biotech Group's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688656 vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, HOB Biotech Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HOB Biotech Group Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, HOB Biotech Group's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where HOB Biotech Group's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
HOB Biotech Group (SHSE:688656) has a Debt-to-EBITDA of 0.47 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on HOB Biotech Group. This is 22% below median its historical median of 0.60. Over the past decade, HOB Biotech Group's Debt-to-EBITDA has ranged from 0.25 to 3.32. According to the industry distribution chart, HOB Biotech Group ranks #200 out of 475 companies in the Medical Devices & Instruments industry, placing it in the top 42.1%.
Is HOB Biotech Group's Debt-to-EBITDA too high?
HOB Biotech Group's current Debt-to-EBITDA of 0.47 is 22% below median its 10-year median of 0.60. Over the past 10 years, this metric has ranged from a low of 0.25 to a high of 3.32. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.60. HOB Biotech Group's value of 0.47 is 70.6% below this industry median. Based on the distribution chart, HOB Biotech Group ranks #200 out of 475 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, HOB Biotech Group has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does HOB Biotech Group's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, HOB Biotech Group ranks #200 out of 475 companies for Debt-to-EBITDA. This puts HOB Biotech Group in the upper half of its industry. The industry median Debt-to-EBITDA is 1.60. HOB Biotech Group's value of 0.47 is 70.6% below this benchmark. Historically, HOB Biotech Group's own Debt-to-EBITDA has ranged from 0.25 to 3.32 over the past decade. While the company's 10-year median is 0.60 vs. the industry median of 1.60, HOB Biotech Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.60, based on 475 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HOB Biotech Group's current Debt-to-EBITDA of 0.47 is 70.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on HOB Biotech Group. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HOB Biotech Group's current Debt-to-EBITDA is 0.47, which is 22% below median its own 10-year median of 0.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HOB Biotech Group stock overvalued right now?
Based on GuruFocus' analysis, HOB Biotech Group (SHSE:688656) is currently considered Fairly Valued. The stock's GF Value™ is ¥94.07, compared to a current price of ¥101.78 — trading 8.2% above its estimated fair value. The current Debt-to-EBITDA is 0.47, which is 22% below median its 10-year median of 0.60 and 70.6% below the Medical Devices & Instruments industry median of 1.60. HOB Biotech Group's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For HOB Biotech Group (SHSE:688656), the current Debt-to-EBITDA is 0.47 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HOB Biotech Group (SHSE:688656) Overvalued in 2026?
Based on GuruFocus' analysis, HOB Biotech Group stock appears to be overvalued.
The current stock price of ¥101.78 is trading 8.2% above its estimated GF Value™ of ¥94.07.
GuruFocus considers HOB Biotech Group to be Fairly Valued.
Key valuation signals for SHSE:688656:
Debt-to-EBITDA: 0.47 (22% below median its 10-year median of 0.60)
GF Value™: ¥94.07 vs. price of ¥101.78 (8.2% above fair value)
Industry Position: 70.6% below the Medical Devices & Instruments median (#200 of 475)
No single metric tells the full story. See the SHSE:688656 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HOB Biotech Group Corp Ltd is an in vitro diagnostic company. The firm is specialized in providing diagnostic tools to laboratories and hospitals for the improvement of allergy and autoimmune disease patient care.
84GF Score
Get the complete analysis for SHSE:688656
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688656 has been successfully added to your 
